Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: sarepta.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $182.00 | Sector Perform → Outperform | RBC Capital Mkts |
6/26/2024 | $172.00 → $176.00 | Buy → Neutral | Citigroup |
5/31/2024 | $157.00 | Overweight | Piper Sandler |
5/28/2024 | $157.00 → $142.00 | Outperform → Sector Perform | RBC Capital Mkts |
5/14/2024 | $180.00 | Perform → Outperform | Oppenheimer |
1/31/2024 | $170.00 | Outperform | BMO Capital Markets |
12/13/2023 | $113.00 | Buy | Citigroup |
12/12/2023 | $109.00 | Buy | Deutsche Bank |
11/21/2023 | $224.00 | Outperform | Wedbush |
10/31/2023 | $166.00 → $40.00 | Overweight → Neutral | Cantor Fitzgerald |
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
3 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
Net product revenues for the second quarter 2024 totaled $360.5 million, a 51% increase over the same quarter of the prior year ELEVIDYS net product revenue for the quarter totaled $121.7 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $2.4 million Achieved GAAP net income of $6.5 million for the second quarter 2024 and non-GAAP net income of $46.7 million for the same period Sarepta provides net product revenues guidance of $2.9 billion to $3.1 billion for 2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024. "The second quar
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in July 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received in the aggregate 14,495 restricted stock units ("RSUs"). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully ve
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, al
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 23 individuals hired by Sarepta in June 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 5,100 shares of Sarepta's common stock, and in the aggregate 19,980 restricted stock units ("RSUs"). The options have an exercise price of $158.00 per share, which is equal to
– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted tr
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received in the aggregate 8,975 restricted stock units ("RSUs"). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
– TIME recognizes Dr. Mendell's decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular dystrophy Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a new age of treatment for
Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9 million Achieved GAAP Earnings of $36.1 million for the first quarter 2024 and non-GAAP Earnings of $78.2 million for the same period Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. "We are pleased to announce another strong quarter of growth from our four approved therapies, posting net product revenue of $359.5 million, a 55% increase over the same quarter of the prior year, and achiev
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling
For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. Elevidys was previously approved under accelerated approval for amb
Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling
Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-10) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling
For Immediate Release: June 22, 2023 Today, the U.S. Food and Drug Administration approved Elevidys, the first gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who do not have a pre-existing medical reason preventing treatment with this therapy. “Today’s approval addresses an urgent unmet medical need
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-5) with active ingredient CASIMERSEN has changed to 'Approval' on 03/23/2023. Application Category: NDA, Application Number: 213026, Application Classification: Labeling
Submission status for SAREPTA THERAPS INC's drug EXONDYS 51 (SUPPL-29) with active ingredient ETEPLIRSEN has changed to 'Approval' on 01/18/2022. Application Category: NDA, Application Number: 206488, Application Classification: Labeling
Submission status for SAREPTA THERAPS INC's drug EXONDYS 51 (SUPPL-28) with active ingredient ETEPLIRSEN has changed to 'Approval' on 01/18/2022. Application Category: NDA, Application Number: 206488, Application Classification: Labeling
Submission status for SAREPTA THERAPS INC's drug EXONDYS 51 (SUPPL-27) with active ingredient ETEPLIRSEN has changed to 'Approval' on 01/18/2022. Application Category: NDA, Application Number: 206488, Application Classification: Labeling
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (ORIG-1) with active ingredient CASIMERSEN has changed to 'Approval' on 02/25/2021. Application Category: NDA, Application Number: 213026, Application Classification: Type 1 - New Molecular Entity
Net product revenues for the second quarter 2024 totaled $360.5 million, a 51% increase over the same quarter of the prior year ELEVIDYS net product revenue for the quarter totaled $121.7 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $2.4 million Achieved GAAP net income of $6.5 million for the second quarter 2024 and non-GAAP net income of $46.7 million for the same period Sarepta provides net product revenues guidance of $2.9 billion to $3.1 billion for 2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024. "The second quar
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, al
– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted tr
Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9 million Achieved GAAP Earnings of $36.1 million for the first quarter 2024 and non-GAAP Earnings of $78.2 million for the same period Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. "We are pleased to announce another strong quarter of growth from our four approved therapies, posting net product revenue of $359.5 million, a 55% increase over the same quarter of the prior year, and achiev
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all pho
– Net product revenues for the fourth quarter 2023 totaled $365.1 million, a 55% increase over the same quarter of the prior year; 2023 net product revenues for the full-year 2023 totaled $1.1 billion, an increase of approximately 36% over the prior year – ELEVIDYS revenues for the quarter totaled $131.2 million and for full-year totaled $200.4 million Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023. "We are pleased to report another strong quarter and year of performance serving the patient community. With our three approved PMO therapies, EXONDYS 51, VYOND
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register usin
At target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20) The data support a positive benefit-risk profile for SRP-5051 Sarepta will host a conference call at 8:30 a.m. Eastern time on Jan. 29, 2024 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that enrolled patients aged 8 to 21 years. SRP-5051 is a next-generation peptide phosphorodiamidate morpholino oligomer (PPMO
ELEVIDYS net product revenues for the quarter totaled $69.1 million Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2023 totaled $331.8 million Net product revenues for the third quarter 2023 totaled $309.3 million, a 49% increase over the same quarter of prior year Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023. "The third quarter was a defining moment for Sarepta. We launched ELEVIDYS, our fourth therapy and the first gene therapy for boys with Duchenne muscular dystrophy, we continued to drive great performa
– Results support submission of an efficacy supplement to the BLA; US FDA has indicated openness to reviewing the data for label expansion based on the totality of evidence from EMBARK – In EMBARK, participants treated with ELEVIDYS (delandistrogene moxeparvovec-rokl) showed an increase on the North Star Ambulatory Assessment, a measure of motor function, compared to placebo-treated patients at 52 weeks, although the primary endpoint was not met – Robust, statistically significant results on all key pre-specified secondary endpoints, including time to rise (p=0.0025), and 10-meter walk test (p=0.0048), demonstrated evidence of a clinically meaningful treatment benefit that was similar i
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
RBC Capital Mkts upgraded Sarepta Therapeutics from Sector Perform to Outperform and set a new price target of $182.00
Citigroup downgraded Sarepta Therapeutics from Buy to Neutral and set a new price target of $176.00 from $172.00 previously
Piper Sandler initiated coverage of Sarepta Therapeutics with a rating of Overweight and set a new price target of $157.00
RBC Capital Mkts downgraded Sarepta Therapeutics from Outperform to Sector Perform and set a new price target of $142.00 from $157.00 previously
Oppenheimer upgraded Sarepta Therapeutics from Perform to Outperform and set a new price target of $180.00
BMO Capital Markets initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $170.00
Citigroup resumed coverage of Sarepta Therapeutics with a rating of Buy and set a new price target of $113.00
Deutsche Bank initiated coverage of Sarepta Therapeutics with a rating of Buy and set a new price target of $109.00
Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $224.00
Cantor Fitzgerald downgraded Sarepta Therapeutics from Overweight to Neutral and set a new price target of $40.00 from $166.00 previously
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to the Sarepta board that will help guide the company on its mission to change the course of life-threatening rare diseases. "We're pleased to welcome two new board members whose participation will contribute to the realization of Sarepta's strategic vision to create transformative therapies for patients with rare diseases," said M. Kathleen Behrens, Ph.D., Chai
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan currently serves as Executive Vice President and Chief Financial Officer (CFO) of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases. At Sarepta and as a member of Sarepta's Executive Committee, he leads f
Gilmore O'Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022 CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company's head of research and development (R&D) and will continue to serve in the role of chief scientific officer. Gilmore O'Neill, M.B., M.M.Sc., who has served as head of R&D since 2018, will leave the Company at the end of November and remain in a consulting capacity until
A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company's board CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology (Caltech), and serves on the board of directors for Merck and on the scientific advisory board of Rubryc Therapeutics. "We are delighted to welcome Dr. Mayo to the Sarepta Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel. A veteran life sciences executive, Mr. Howton brings to AavantiBio more than two decades of strategic, operational, and legal experience in the biopharmaceutical industry. In his most recent position, Mr. Howton served as Executive Vice President, General Counsel and Corporate Secretary of Sarepta Therapeutics (NASDAQ: SRPT), where he led Company’s global legal and compliance functions and oversaw quality assurance and information technology. Previo
CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in December 2020. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 4,525 shares of Sarepta's common stock, and in the aggregate, 1,720 restricted stock units (“RSUs”). The options hav
S-8 - Sarepta Therapeutics, Inc. (0000873303) (Filer)
10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)
DEF 14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)
ARS - Sarepta Therapeutics, Inc. (0000873303) (Filer)
DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)
S-8 POS - Sarepta Therapeutics, Inc. (0000873303) (Filer)
S-8 POS - Sarepta Therapeutics, Inc. (0000873303) (Filer)
S-8 POS - Sarepta Therapeutics, Inc. (0000873303) (Filer)
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an average annual return of 21.14%. Currently, Sarepta Therapeutics has a market capitalization of $13.74 billion. Buying $1000 In SRPT: If an investor had bought $1000 of SRPT stock 10 years ago, it would be worth $6,642.60 today based on a price of $145.34 for SRPT at the time of writing. Sarepta Therapeutics's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Be
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo Alto Networks, Inc. (NASDAQ:PANW) for the charitable trust. On July 11, Barclays analyst Saket Kalia maintained Fortinet with an Equal-Weight and lowered the price target from $75 to $70. When asked about Air Products and Chemicals, Inc. (NYSE:APD), Cramer said Linde plc (NASDAQ:LIN) is a “much better run company, and that's why Air Products isn't doing as well, and Linde's doing spectacularly.” On July 16, Air Products named Eric Guter as vice president of Investor Relations effective Sept. 30 succeeding Sidd Manjeshwar. Sarepta Therapeutics, Inc. (N
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 8.61% on an annualized basis producing an average annual return of 19.45%. Currently, Sarepta Therapeutics has a market capitalization of $14.37 billion. Buying $100 In SRPT: If an investor had bought $100 of SRPT stock 10 years ago, it would be worth $596.22 today based on a price of $152.00 for SRPT at the time of writing. Sarepta Therapeutics's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzing
Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 13 6 0 0 Last 30D 0 1 0 0 0 1M Ago 3 9 4 0 0 2M Ago 3 3 2 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $182.8, a high estimate of $235.00, and a low estimate of $128.00. Markin
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $205 price target.
Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $235 price target.
Whales with a lot of money to spend have taken a noticeably bearish stance on Sarepta Therapeutics. Looking at options history for Sarepta Therapeutics (NASDAQ:SRPT) we detected 14 trades. If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 50% with bearish. From the overall spotted trades, 5 are puts, for a total amount of $374,000 and 9, calls, for a total amount of $1,862,920. Projected Price Targets Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $180.0 for Sarepta Therapeutics over the last 3 months. Volume &
Citigroup analyst David Hoang downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and raises the price target from $172 to $176.
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 7.68% on an annualized basis producing an average annual return of 18.37%. Currently, Sarepta Therapeutics has a market capitalization of $15.43 billion. Buying $1000 In SRPT: If an investor had bought $1000 of SRPT stock 10 years ago, it would be worth $5,478.18 today based on a price of $163.19 for SRPT at the time of writing. Sarepta Therapeutics's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Ben
Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $165 to $200.
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)